IL-6 and MYC collaborate in plasma cell tumor formation in mice
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Interleukin-6 (IL-6) plays a critical role in the natural history of human plasma cell neoplasms (PCNs), such as plasma cell myeloma and plasmacytoma (PCT). IL-6 is also at the center of neoplastic plasma cell transformation in BALB/c (C) mice carrying a transgene, H2-Ld-IL6, that encodes human IL-6 under control of the major histocompatibility complex H2-Ld promoter: strain C.H2-Ld-IL6. These mice are prone to PCT, but tumor development is incomplete with long latencies (∼ 40% PCT at 12 months of age). To generate a more robust mouse model of IL-6–dependent PCN, we intercrossed strain C.H2-Ld-IL6 with strains C.iMycEμ or C.iMycCα, 2 interrelated gene-insertion models of the chromosomal T(12;15) translocation causing deregulated expression of Myc in mouse PCT. Deregulation of MYC is also a prominent feature of human PCN. We found that double-transgenic C.H2-Ld-IL6/iMycEμ and C.H2-Ld-IL6/iMycCα mice develop PCT with full penetrance (100% tumor incidence) and short latencies (3-6 months). The mouse tumors mimic molecular hallmarks of their human tumor counterparts, including elevated IL-6/Stat3/Bcl-XL signaling. The newly developed mouse strains may provide a good preclinical research tool for the design and testing of new approaches to target IL-6 in treatment and prevention of human PCNs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Insertion of Myc into Igh Accelerates Peritoneal Plasmacytomas in Mice
Park, S. S., Shaffer, A. L., Kim, J. S., duBois, W., Potter, M., Staudt, L. M., & Janz, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1222 · Cited by 27
Self-citation
Cited by
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Varzaneh, F. N., Keller, B., Unger, S., Aghamohammadi, A., Warnatz, K., & Rezaei, N. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0053-0 · Cited by 62
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
ZHAO, W., SU, W., KUANG, P., ZHANG, L., LIU, J., YIN, Z., & WANG, X. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1497 · Cited by 51
Metadata
- Authors
- Rutsch, S., Neppalli, V. T., Shin, D.-M., DuBois, W., Morse, H. C., Goldschmidt, H., & Janz, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-03-04
- Volume
- 115
- Issue
- 9
- Pages
- 1746-1754
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1996660822
- Cited by
- 58
- References
- 7
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-6 and MYC collaborate in plasma cell tumor formation in mice. https://app.cochat.ai/papers/10.1182/blood-2009-08-237941
- The paper
- Rutsch, S., Neppalli, V. T., Shin, D.-M., DuBois, W., Morse, H. C., Goldschmidt, H., & Janz, S. (2010). IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood. https://doi.org/10.1182/blood-2009-08-237941
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.